Treatment of Renal Fibromuscular Dysplasia
Percutaneous transluminal renal angioplasty (PTRA) without stenting is the treatment of choice for renal fibromuscular dysplasia with hemodynamically significant stenosis and hypertension. 1
Initial Management Approach
All patients with renal FMD should receive medical therapy to reduce blood pressure as first-line treatment 1. However, the definitive treatment strategy differs fundamentally from atherosclerotic renal artery stenosis:
When to Refer for Revascularization
Revascularization should be considered for patients with: 2, 1
- Uncontrolled hypertension despite maximally tolerated pharmacotherapy
- Resistant hypertension (requiring ≥3 antihypertensive medications)
- Progressive renal function decline
- Recent onset hypertension in young patients (especially women)
- Hypertension with unexplained unilateral small kidney
Patients with confirmed renal FMD should be referred to a hypertension specialist 2, as this is now recognized as a systemic disease affecting multiple vascular beds (carotid, coronary, and other major arteries) 1.
Revascularization Technique
Primary Intervention: Balloon Angioplasty Alone
The 2024 ESC Guidelines (most recent) recommend renal artery angioplasty without stenting as a Class IIa recommendation 1. This approach:
- Can restore renal perfusion pressure and lower blood pressure
- May cure hypertension in some patients, particularly those with recent onset 3, 4
- Achieves complete abolition of pressure gradients in most cases 5
- Works best in unifocal disease and younger patients 5
Stenting: Bailout Only
Stenting is NOT recommended as primary therapy 2, 6, 1. Stent placement should only be used for:
- Peri-procedural dissection 2
- Balloon angioplasty failure 2, 7
- Progressive dissection during the procedure 6
The rationale: FMD lesions are typically truncal or distal (middle and distal two-thirds of the renal artery), unlike atherosclerotic lesions which are ostial 1, 8. The altered vascular wall and uneven lumen in FMD increase complication risks with stenting 9.
Surgical Revascularization
Open surgical reconstruction should be considered for: 2, 6, 10
- Complex lesions less amenable to angioplasty
- Stenosis associated with complex aneurysms
- Disease extending into segmental arteries 6
- Restenosis despite 2 unsuccessful attempts at angioplasty 2
- Failed or technically unfeasible endovascular intervention 1
Medical Management When Revascularization Not Feasible
If PTRA is not technically feasible, RAS blockers (ACE inhibitors or ARBs) are the drugs of choice 1. However, critical caveats apply:
- Careful monitoring of renal function is mandatory 1
- Avoid in tight bilateral stenoses or stenosed solitary functioning kidney (risk of acute renal failure) 1
- Blood pressure must be controlled to prevent dissection in other vascular beds 1
Key Clinical Distinctions from Atherosclerotic Disease
This is crucial: Unlike atherosclerotic renal artery stenosis, where multiple RCTs showed no benefit of revascularization over medical therapy alone 3, 7, 4, FMD responds favorably to angioplasty and may be curative 3, 4. The 2025 AHA/ACC Guidelines explicitly state that revascularization "may cure hypertension in some adults with nonatherosclerotic renal artery stenosis" 3.
Common Pitfalls to Avoid
Do not treat FMD like atherosclerotic disease: The evidence against revascularization in atherosclerotic RAS does not apply to FMD 3, 7, 4
Do not routinely place stents: This increases complications without benefit in FMD 2, 1
Do not delay diagnosis: Young women with hypertension should be screened, as early intervention yields better outcomes 5, 11
Do not forget systemic evaluation: Screen for carotid and other arterial involvement, as FMD is a systemic disease 1
Monitor for restenosis: Continued follow-up is necessary as stenosis can recur 11, 12
Outcomes
PTRA for FMD typically achieves: